Skip to content

PP&E (Net) at other companies

ALN
Alnylam PharmaceuticalsALNY
$518.26M+3.9%
Septerna, Inc. logo
Septerna, Inc.SEPN
$4.33M-14.2%
Regenxbio logo
RegenxbioRGNX
$101.87M-11.0%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$23.57M+0.2%
Opko Health logo
Opko HealthOPK
$72.59M+2.0%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$163.02M-17.6%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's PP&E (net)?
Tectonic Therapeutics (TECX) reported PP&E (net) of $1.02M in Q1 2026.
How has Tectonic Therapeutics's PP&E (net) changed year-over-year?
Tectonic Therapeutics's PP&E (net) decreased by 47.0% year-over-year, from $1.92M to $1.02M.
What is the long-term trend for Tectonic Therapeutics's PP&E (net)?
Over 5 years (2020 to 2025), Tectonic Therapeutics's PP&E (net) has grown at a -17.3% compound annual growth rate (CAGR), from $3.06M to $1.19M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.